Investigative Landscape in Advanced Non-Melanoma Skin Cancers
Priyanka Reddy1, Min Yao2, Monaliben Patel3
1Department of Hematology and Oncology, Department of Radiation Oncology, Case Comprehensive Cancer Center, 11100 Euclid Ave., Cleveland, OH, 44106, USA.
Opinion Statement:
Advanced non-melanoma skin cancers have been challenging to treat due to limited treatment options. Treatment paradigm has shifted with the approval of immunotherapeutic agents cemiplimab and pembrolizumab which have been a key development and have changed the landscape of advanced or metastatic squamous cell skin cancers. Hedgehog inhibitors, vismodegib and sonidegib, remain upfront options for advanced or metastatic basal cell carcinomas. Current clinical trials are continuing to evaluate the use of immune checkpoint inhibitors and hedgehog pathway inhibitors. There is further need for ongoing research and development of new therapies in both malignancies.
Insights
Advanced non-melanoma skin cancers, including squamous cell and basal cell carcinomas, now have improved treatment options. Immunotherapies like cemiplimab and hedgehog inhibitors like vismodegib offer new hope, with ongoing research for further advancements.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Advanced non-melanoma skin cancers present significant therapeutic challenges.
- Limited effective treatment options historically impacted patient outcomes.
- Recent advancements have begun to reshape the treatment landscape.
Purpose of the Study:
- To review the current treatment paradigms for advanced non-melanoma skin cancers.
- To highlight the impact of newly approved immunotherapies and hedgehog inhibitors.
- To identify areas for future research and therapeutic development.
Main Methods:
- Review of current literature and clinical trial data.
- Analysis of treatment outcomes for immunotherapeutic agents (cemiplimab, pembrolizumab).
- Evaluation of hedgehog pathway inhibitors (vismodegib, sonidegib) in clinical practice.
Main Results:
- Immunotherapies have transformed the management of advanced or metastatic squamous cell skin cancers.
- Hedgehog inhibitors are established first-line treatments for advanced or metastatic basal cell carcinomas.
- Ongoing clinical trials are exploring novel combinations and applications of these targeted therapies.
Conclusions:
- The advent of cemiplimab, pembrolizumab, vismodegib, and sonidegib has significantly improved treatment options for advanced non-melanoma skin cancers.
- Continued research into immune checkpoint inhibitors and hedgehog pathway inhibitors is crucial.
- Further development of novel therapeutic strategies is needed for both squamous cell and basal cell carcinomas.
